Corporate News
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
Berlin, May 6, 2008 – Bayer Schering Pharma’s new low-dose oral contraceptive YAZ® has been approved in the EU.YAZ® will be the first oral contraceptive on the European market containing the unique... more
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for... more
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
Leverkusen, April 21, 2008 – Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District... more
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
World Hemophilia Day on April 17th more
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly more
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit more
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Leverkusen, Germany, / Minneapolis, MN, USA – Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered... more
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan more
Bayer extends product portfolio for liver cancer patients in Japan
Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan more
Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer... more
US Food and Drug Administration Approves RECOTHROM™
Leverkusen – Bayer HealthCare announced today that its partner, ZymoGenetics Inc., received US Food and Drug Administration (FDA) approval of RECOTHROM™ Thrombin, topical (recombinant) for use as a... more
Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project
A new high-potential biofuel crop more
Expanded Labeling for MabCampath® in Europe
B-cell chronic lymphocytic leukemia (B-CLL): more